Breakthrough in scaling up life-changing stem cell production
Scientists from the U.K. and Sweden have discovered a new method of creating human stem cells that could solve the problem of meeting large-scale production needs, allowing researchers to fully realize the potential of stem cells for understanding and treating disease.
Human pluripotent stem cells are undifferentiated cells that have the unique potential to develop into all the different types of
cells in the body. With applications in disease modeling, drug screening, regenerative medicine and tissue engineering, there is already an enormous demand for these cells, and that demand will continue grow as their use in clinical settings and the pharmaceutical industry increases.
The research results, published in Nature Communications in July, describe how the scientific team from The University of Nottingham’s Wolfson Centre for Stem Cells, Tissue Engineering and Modelling at Uppsala University in Sweden and GE Healthcare also in Sweden have identified and improved human stem cell culture methods that could lead to quicker and cheaper large scale industrial production of human pluripotent stem cells.
By using a protein derived from human blood called Inter-alpha inhibitor, the team has grown human pluripotent stem cells in a minimal medium without the need for costly and time-consuming biological substrates. Inter-alpha inhibitor is found in human blood at high concentrations, and is currently a by-product of standard drug purification schemes.
The human serum-derived protein can make stem cells attach to unmodified tissue culture plastic, eliminating the need for coating in defined human pluripotent stem cell culture, and improving survival capabilities of the stem cells in harsh conditions.
It is the first stem cell culture method that does not require a pre-treated biological substrate for attachment, and therefore, is more cost and time efficient, paving the way for easier and cheaper large-scale production.
Existing methods are time consuming and make developing human stem cell cultures prohibitively costly. This new method has the potential to save time and money in large-scale and high-throughput cultures, and be highly valuable for both basic research and commercial applications.
The work began at Uppsala University, and the study’s first author, Sara Pijuan-Galitó PhD., is continuing her work as a Swedish Research Council Research Fellow at Nottingham.
Researchers now intend to combine Inter-alpha inhibitor protein with an innovative hydrogel technology to improve on current methods for controlling cell differentiation, and also apply it to disease modelling. The discovery, according to the findings, will help facilitate research into many diseases although their focus is currently on understanding rare conditions like Multiple Osteochondroma) at the cellular level. The aim is to replicate the 3 dimensional environment that cells experience within the body so that lab-bench biology is more accurate in modelling diseases.
Pijuan-Galitó has been awarded the Sir Henry Wellcome Postdoctoral Fellowship at Nottingham University for her work on the research, which will enable her to combine Inter-alpha inhibitor with improved synthetic polymers in collaboration with fellow regenerative medicine pioneers Professor Morgan Alexander and Professor Chris Denning. The team plans to further improve on current human stem cell culture by designing an economical and safe method that can be easily translated to large-scale production and can deliver billions of stem cells necessary move cellular therapeutics forward in patient settings.
The study, titled “Human serum-derived protein removes the need for coating in defined human pluripotent stem cell culture,” was published in Nature Communications in July, 2016.
###
- Published in Corporate News / Blog
Global Stem Cells Group to offer Stem Cell Training Certification course Oct. 1 and 2, Following International Symposium in Buenos Aires
MIAMI, Sept. 13, 2016-Global Stem Cells Group announced plans to hold a stem cell training certification course Oct. 1 -2, 2016 following the 3rd annual Global Stem Cells Group International Symposium on Stem Cells and Regenerative Medicine in Buenos Aires. The symposium will take place Sept. 28, 2016.
The two-day, hands-on training course covers the latest technology and procedures in SVF and bone marrow stem cell techniques. Practitioners learn skills that can be used to treat patients in their practices, and for career advancement. The SVF and bone marrow aspiration course was developed for physicians and high-level practitioners to learn techniques in harvesting and rein
The course will be taught by GSCG Advisory Board members Joseph Purita, M.D. and Silvina Pastrana, M.D.
The stem cell training certification course will be held at the Global Subsidiary Stem Cell Center Network in Puerto Madero Buenos Aires immediately following the 3rd annual International Symposium on Stem Cells and Regenerative Medicine.
Since 2014, Global Stem Cells Group has joined forces with some of the most prestigious regenerative medicine practitioners in South America as it focuses on growing its services throughout the global community. Stem cell therapies continue to revolutionize the anti-aging aesthetics industry and help improve the quality of life for patients suffering from some chronic conditions.
To learn more about the 3rd Annual International Symposium on Stem Cells and Regenerative Medicine, visit the Global Stem Cells Group website, email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.
About Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
To view this press release live online, click here
###
- Published in Press Releases
Global Stem Cells Group to Attend the First Latin American Congress on Sports Medicine in Panama
MIAMI, Sept. 9, 2016—Global Stem Cells Group will attend the Colombian Association of Sports Medicine’s First Latin American Congress on Sports Medicine, Injuries, Treatment and Rehabilitation in Panama City, Panama Sept. 22 – 24, 2016. The Panama Congress will focus on a variety of Sports Medicine specialties presented in an academic activity framework.
The congress will host a diverse range of esteemed guests, including physicians, athletes, athletic coaches, physical therapists, medical exercise physiologists, orthopedists, physical medicine and rehabilitation (PM&R) physicians (physiatrists), Paralympics athletes, endocrinologists, diabetologists, orthopedic surgeons, internists, physical educators, pain specialists, nutrition and dietetic specialists, psychologists, neuro surgeons and neuro rehabilitation specialists.
The event, to be hosted at the Hotel Riu Plaza in the heart of Panama City’s financial district, will provide a dynamic atmosphere showcasing local, national, international and Latin American ambience.
To learn more about the First Latin American Congress on Sports Medicine, visit the event website.To learn more about Global Stem Cells Group, visit the GSCG website, email bnovas(at)stemellsgroup.com, or call 305-560-5337.
About Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
To review this press release live online, click here
###
- Published in Press Releases
Global Stem Cells Group Announces Speaker Lineup for the 3rd Annual International Symposium on Stem Cells and Regenerative Medicine
MIAMI, Sept. 9, 2016—Global Stem Cells Group has announced its lineup of speakers for the 3rd Annual International Symposium on Stem Cells and Regenerative Medicine, to be held Sept. 28, 2016 in Buenos Aires, Argentina. In keeping with tradition, the symposium will be hosted by GSCG in collaboration with Julio Ferreira, M.D., President of the South American Academy Cosmetic Surgery.
The symposium will be a gathering of many of the world’s most respected authorities on stem cell and regenerative medicine, who will share the latest findings and showcase advancements in research and therapies on a global level. The interdisciplinary team of leading international stem cell experts will provide a full day of high-level scientific lectures geared to medical professionals. Pioneers and luminaries in stem cell medicine who will serve as featured speakers at the event include:
Joseph Purita, M.D., USA
Musculoskeletal and antiaging applications of stem cells.
Joseph Purita, M.D., is an internationally recognized orthopedic surgeon and pioneer in the application of stem cells and PRP therapies for orthopedic injuries and diseases. Dr. Purita pioneered laser techniques in orthopedic surgery, and specializes in the treatment of high-performance athletes. Dr. Purita is a member of the Global Stem Cells Group Advisory Board.
[su_spacer]
Enrique Testart,, M.D., Chile
Osteogenesis and the future of heterologous implants.
Enrique Testart, M.D., is a pediatric surgeon specializing in child trauma microsurgery. Dr. Testart has developed distinctive techniques and protocols in cellular therapies and management protocols for musculoskeletal disorders. He has dedicated years to researching and practicing techniques that employ stem cell therapies to enhance conventional surgical techniques to ease patient suffering. Dr. Testart is Global Stem Cells Group’s Chile Representative
Rafael Pérez Franco, M.D., Colombia
Use of cell therapy in the treatment of alopecia.
Rafael Perez Franco, M.D. is director of the Rafael Perez Center for Reconstructive and Aesthetic Surgery in Bogota, Colombia. An expert in his field for more than 10 years, Dr. Perez Franco is a surgeon at the Universidad del Bosque and a plastic surgeon at the Clínica San Rafael in Colombia. Dr. Perez Franco also holds special rotations at Hospital Saint Paul in San Pablo, Brazil and the Clínica Fluminense de Cirugía Plástica and Clínica del Profesor Ivo Pitanguy in Rio de Janeiro. He is a member of the Global Stem Cells Group Advisory Board.
Carlos Chiriboga Assini, M.D., Ecuador
Application of Neural therapy and stem cell therapy in the treatment of injuries for high performance athletes.
Carlos Chirigoba Assini, M.D. serves as Chairman of the Board ar Omnihospital Medical Association in Guayaquil, Ecuador. Dt. Chirigoba Assini specializes in traumatology, orthopedic surgery, and platelet rich plasma (PRP) therapies. He is a member of Omnihospital Medical Association and the American Academy of Antiaging.
Aldo Parodi, M.D. Perú
Aesthetic applications of cellular therapies.
Aldo Parodi, M.D. is a plastic surgeon and laser liposuction specialist with clinical experience in assisted lipotransference. Dr. Parodi offers aesthetic treatments using adipose-derived stem cells at his aesthetic medicine clinic Clinic La Femme in Tacna, Peru. He is a member of the Global Stem Cells Group Advisory Board.
[su_spacer]
Silvina Pastrana, M.D. Argentina.
Implementation of cellular therapies. Presentation of clinical cases.
Silvina Pastrana, M.D. is a surgeon and medical director of the Stem Cell Center Buenos Aires and Regentherapy Puerto Madero. Dr. Pastrana heads a staff of medical specialists in orthopedics, rheumatology, medical clinic and cosmetic surgery, performing procedures incorporating stem cell therapies. She also serves as a staff surgeon for the Hospital Dr. Prof. Luis Güemes, and is a member of the Global Stem Cells Group Advisory Board.
Benito Novas, CEO, Global Stem Cell Group, United States
Developments and Challenges of Regenerative medicine globally.
Benito Novas, founder, CEO and creative director of Global Stem Cells Group, Mr. Novas also spearheaded and launched Stem Cell Training Inc. to provide professional training courses in stem cell therapies for physicians. Mr. Novas oversees Stem Cell Training marketing programs, finance strategies, field operations administration, policies, procedures and accreditation. Prior to founding The Global Stem Cells Group, Mr. Novas was President and CEO of Adimarket, Inc.
Leonardo Tacus, M.D. Argentina
Muscle and tendon injuries in regenerative medicine.
Leonardo Tacus, M.D. is an arthroscopic surgeon specializing in orthopedics, traumatology, and regenerative medicine. Dr. Tacus is the medical director at iar sa Argentina Hospital and Health Care, and co-director of Education Center Graduate Medical Surgery, orthopedics and Trauma (CECOA) in Buenos Aires. He is a founding member of the Argentina Association of Arthroscopy and past secretary of the Argentina Association of Arthroscopy
Daniel Domínguez, Aregntina
Systematics in the preparation of blood components for Regenerative Medicine.
Daniel Domínguez is the operations manager of High Technology Systems S.A. in Buenos Aires. Mr. Dominguez’s background includes hemotherapy and laboratory tech.
Susana Miriam Gjurkan, D.M.D. Argentina
Application of stem cells and PRP in temporomandibular joint ATM (modified technique)
Susana Miriam Gjurkan, D.M.D., is a surgical specialist in orthodontics, cosmetic dentistry, dental implants, preventive dentistry, pediatric dentistry, periodontics, prosthetic dentistry, neurofacial and aesthetic dentistry. She uses stem cells and PRP to treat temporomandibular joint (TMJ) disorders in patients (modified technique). Dr. Gjurkan operates from her clinic, ONE Surgery, in San Miguel de Tucuman, Argentina. She has attended and taught courses in neural therapy, and earned her stem cell certification through Stem Cell Training.
Since 2014, Global Stem Cells Group has joined forces with some of the most prestigious regenerative medicine practitioners in South America as it focuses on growing its services throughout the global community. Stem cell therapies continue to revolutionize the anti-aging aesthetics industry while offering new hope for sufferers of serious chronic debilitating diseases.
To learn more about the 3rd Annual International Symposium on Stem Cells and Regenerative Medicine, visit the Global Stem Cells Group website,email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.
About Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
About Julio Ferreira, M.D.
Julio Ferreira, M.D., President of the South American Academy of Cosmetic Surgery, is a professor at the Institute of Biomedical Sciences, University of Sao Paulo, Brazil. In addition, he is the former President of the International Academy of Cosmetic Surgery 2005/2007; a member and examiner, International Board of Cosmetic Surgery; Corresponding Fellow of the American Academy of Cosmetic Surgery; Honorary Member of the Spanish Society of Cosmetic Medicine and Surgery; Honorary Member of the Eurorusa Confederation of Societies of Aesthetic Plastic Surgery; Honorary Member of the Bulgarian Society of Cosmetic Surgery; Honorary Member of the Chilean Society of Cosmetic Surgery and Lipoplasty; Honorary Member of the Italian Society of Aesthetic Surgery; Honorary Member of the French Society of Aesthetic Surgery; Honorary Member of the Japan Society of Aesthetic Surgery; Honorary Member of the Ecuadorian Society of Medical Aesthetics; Honorary Member of the Peruvian Society of Cosmetic Surgery, and a member of the International Editorial Advisory Board of the American Journal of Cosmetic Surgery.
To view this press release live online, click here
###
- Published in Press Releases
Global Stem Cells Group Subsidiary Adimarket Announces New Closed System Kit for Isolation of Adipose Derived Stem Cells, Development by N-Biotek
MIAMI, Sept.8, 2016—Adimarket, a subsidiary of Global Stem Cells Group, Inc., has announced that Korean biotech leader N-Biotek is developing a new closed system kit containing all of the elements necessary to process adipose tissue and obtain stromal vascular fraction (SVF) in a closed environment.
Created with N-Biotek technology, the system will allow entire procedures to be performed in a sterile closed system.
Adipose derived stem cells (ASCs) are used by physicians for a variety of indications.
Most commonly, ASCs are isolated at the point of care from lipoaspirate (derived from liposuction) tissue as the stromal vascular fraction (SVF), harvested from the patient and immediately administered to the patient as an injection, or used to enrich fat grafts. Isolation of ASCs from adipose tissue is a relatively simple process performed routinely in cell biology laboratories, but isolation at the point of care for immediate clinical administration requires special methodology to prevent contamination, ensure integrity of the clinical procedure, and comply with regulatory requirements.
Once available on the Adimarket product website, the N-Biotek kit can provide a low cost, rapid and simple alternative to traditional methods of isolating ASCs, particularly when smaller quantities are needed.
To learn more about the N-Biotek closed system kit, visit the Adimarket website or the Global Stem Cells website, email bnovas@stemcellsgroup.com, or call 305-560-5337.
About Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
About Adimarket:
Adimarket, Inc., a division of the Global Stem Cells Group, is a cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals. Adimarket
was founded to provide physicians and other health care professionals the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact the practice of stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting edge treatments.
Adimarket’s experienced customer service representatives provide valuable guidance and advice regarding products relevant to individual practices.
About N-Biotek:
Since 1982, N-Biotek has been the leading manufacturer of biomedical and lab equipment worldwide. The Stem Cell Total Solution lab is a culmination of years of dedication to establish compact and customized products in developing the Handy Lab, a personal lab for medical, scientific and university professionals. N-Biotek is known for its high quality, uniquely designed biomedical products and equipment and competitive pricing. Over the years, the company’s products have earned an array of patents, and all meet international standards including CE, ETL, ISO and GMP. N-Biotek also offers real-time monitoring through IT technology.
Since 2010, N-Biotek has expanded significantly, starting new businesses including a stem cell processing system and biological clean room, GMP consulting, validation services and health care services for foreign consumers in order to maintain its lead in the life science field.
To view this press release live online, click here
###
- Published in Press Releases
Global Stem Cells Group Announces Permanent Stem Cell Training Center in South Korea
MIAMI, Aug. 30, 2016 – Global Stem Cells Group and its subsidiary Stem Cell Training, Inc., in a collaborative agreement with South Korean biomedical company N-Biotek, announce the establishment of a permanent stem cell training center at the N-Biotek headquarters in Seoul, South Korea. The announcement comes as part of an ambitious expansion effort between GSCG and N-Biotek to provide stem cell training to qualified physicians worldwide.
Stem Cell Training’s two-day intensive “Adipose-derived Stem Cell and Bone Marrow and Platelet Rich Plasma (PRP)” training course covers concepts in cellular medicine, cell viability basics, basic fat and bone marrow stem cell harvesting, isolation and processing procedures, and principles of platelet rich plasma (PRP) processing.
The Korean training center will offer GSCG’s full array of Stem Cell Training courses including:
The “Cell Assisted Fat Transfer” training course is designed for physicians in the aesthetic and cosmetic fields of medicine. The course specifically focuses on procedures to address facial aging caused by volume loss. Course training covers the basics of facial anatomy, facial aging, and the use of fat harvested from the patient’s own body as a filler.
The “Cell Assisted Fat Transfer” training prepares the physician to perform a mini liposuction procedure in order to retrieve fat for grafting in the patient’s anti-aging treatment. It also provides instruction on placement techniques for female and male patients according to age and ethnicity. Fat is a popular filler in the aesthetic medicine field, as the industry experiences an increase in liposuction procedures, an increased interest in facial re-volumization and body, and a growing appreciation for the regenerative potential of adipose-derived mesenchymal stem cells.
The “Diplomat Cell Therapy and Tissue Engineering” course is offered to physicians and qualified practitioners interested in implementing regenerative medicine therapies. This course offers a detailed, hands-on experience in stem cell characterization and laboratory applications; cell protocols including culture, plating, trypsinization, harvesting and cryopreservation; instruction in applying quality control tests including cell count, viability, flow cytometry, endotoxin, mycoplasma and sterility; the ability to perform cGMP functions including clean room maintenance, gowning and environmental monitoring, and new insight and relevant applications of stem cell processing and regulations in a certified facility.
The “Online SVF and Bone Marrow” training course is an online stem cell training course that provides physicians an opportunity to take the clinical training course in a web based format presented as video and voiced over slides. The online course content is consistent with Stem Cell Training’s clinical training course, as it focuses on autologous cellular treatments such as adult stem cells and platelet rich plasma (PRP). Attendees learn how to extract lipoaspirate and bone marrow aspirate, and how to isolate adipose and bone marrow derived stem cells.
In addition, all techniques and materials presented in the training videos are accompanied with detailed protocols.
This course also provides attendees with the tools necessary to implement regulatory and clinical guidelines when setting up a GMP facility; copies of presentations, procedural protocols and all forms associated with a GMP facility; the ability to perform clinical procedures including lipoaspirate and bone marrow isolation; the ability to reintroduce stem cells for various indications, and case books and full protocols for approximately 30 indications.
The two-day online clinical course includes in-clinic procedural videos, recorded didactic lectures, additional information and videos on regenerative medicine, and digital versions of course procedures, protocols and videos.
Stem Cell Training’s experienced and knowledgeable trainers will cover indications, contraindications, patient selection, pre- and post-treatment instructions, and treatment alternatives for autologous facial fat transfer. In addition, participants will learn to analyze anatomy for appropriate areas of facial enhancement; learn various injection techniques to correct temporal hollows, volume loss, tear trough deformity, pre jowl sulcus, malar fat pad, submalar areas, and melomental and nasolabial folds; learn to revent and manage cell-assisted autologous facial fat transfer complications, and understand anesthetic techniques.
To learn more about the stem cells training course center in South Korea, visit the Global Stem Cells Group website, or the Stem Cell Training website, email bnovas@stemcellsgroup.com, or call +1 305 560 5337
About Global Stem Cell Group:
Global Stem Cells Group is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
About Stem Cell Training, Inc.:
Stem Cell Training, Inc. is a multi-disciplinary company offering coursework and training in 35 cities worldwide. The coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatments.
About N-Biotek:
Since 1982, N-Biotek has been the leading manufacturer of biomedical and lab equipment worldwide. The Stem Cell Total Solution lab is a culmination of years of dedication to establish compact and customized products in developing the Handy Lab-a personal lab for medical, scientific and university professionals. N-Biotek is known for its high quality, uniquely designed biomedical products and equipment and competitive pricing. Over the years, the company’s products have earned an array of patents, and all meet international standards including CE, ETL, ISO and GMP. N-Biotek also offers real-time monitoring through IT technology.
Since 2010, N-Biotek has expanded significantly, starting new businesses including a stem cell processing system and biological clean room, GMP consulting, validation services and health care services for foreign consumers in order to maintain its lead in the life science field.
To view this press release live online, click here
###
- Published in Press Releases
Global Stem Cells Group Expects Record Attendance at 3rd Annual International Symposium on Stem Cells and Regenerative Medicine in Buenos Aires
Buenos Aires stem cell symposium scheduled for Sept. 28, 2016.
MIAMI, Aug. 30, 2016 – Global Stem Cells Group, in conjunction with Julio Ferreira, M.D., President of the South American Academy Cosmetic Surgery, will host the 3rd annual Global Stem Cells Group International Symposium on Stem Cells and Regenerative Medicine Sept. 28, 2016. The event, expected to attract a record number of physicians, researchers and regenerative medicine experts from around the world, offers an opportunity for many of the world’s most respected authorities on stem cell and regenerative medicine to showcase advancements in research and therapies on a global level.
According to Benito Novas, Global Stem Cells Group CEO, the world-class event will showcase the historic advances stem cell medicine has achieved since the first symposium was held just two years ago in 2014.
“Back in 2014, our goal was to help clear up old misconceptions and change outdated attitudes by educating people on the wide range of illnesses and injuries to which stem cell therapies were already being applied,” Novas says. “We set out to establish a dialogue between researchers and practitioners in order to help move stem cell therapies from the lab to the physician’s office.
“This year, we will be able to showcase how far stem cell therapies have come since then, and provide some of the most influential leaders that understand the potential of these therapies and have dedicated their careers to making them a reality.”
Since 2014, Global Stem Cells Group has joined forces with some of the most prestigious regenerative medicine practitioners in South America as it focuses on growing its services throughout the global community. Stem cell therapies continue to revolutionize the anti-aging aesthetics industry while offering new hope for sufferers of serious chronic debilitating diseases.
To learn more about the 3rd Annual International Symposium on Stem Cells and Regenerative Medicine, visit the Global Stem Cells Group website, email bnovas@stemcellsgroup.com, or call 305-560-5337.
About Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
About Julio Ferreira, M.D.
Julio Ferreira, M.D., President of the South American Academy of Cosmetic Surgery, is director of Clinica Ferreira in Argentina and a professor at the Institute of Biomedical Sciences, University of Sao Paulo, Brazil.
Julio Ferreira, M.D., is an internationally recognized and respected cosmetic surgeon and professor of medicine and aesthetic surgery at the Institute of Biomedical Sciences, University of Sao Paulo, Brazil;
As director of Clinica Ferreira in Argentina, Dr. Ferreira is dedicated to the combination of art and science in aesthetic medicine.
To view this press release live online, click here
###
- Published in Press Releases
Enrique Testart, M.D.
Enrique Testart, M.D., Global Stem Cells Group’s Chief Medical Officer (CMO), is a surgeon specializing in child trauma microsurgery.
Dr. Testart is also a medical entrepreneur and founder of Consortia Innovas S.A. in Santiago, Chile, dedicated to consulting and clinical health management for clinical management firms and research and development-oriented planners in the latest treatments in regenerative medicine as they become available.
A native of Santiago, Chile, Dr. Testart’s medical studies took him all over the world, including orthopedics studies under the direction of Prof. Jean Paul Metaizeau, M.D. in France.
He is in charge of all Global Stem Cells Group divisions and programs in Chile, including patient recruitment through Cellgenic, medical training and certification through Stem Cell Training Inc., and everything related to the sale of equipment disposable through Adimarket.
- Published in Advisory Board Members
The Language of Stem Cell Medicine: What are They? What Makes Them so Special? And What do all Those Acronyms Mean?
Stem cell medicine is based on the concept that physicians can harness the body’s own reserves to heal itself, rather than relying exclusively on drugs or invasive surgical procedures. Stem cell medicine works by deals engineering human stem cells to replace or restore damaged or diseased organs or tissue, or establish normal function in them. While regenerative medicine primarily includes therapies a that utilize stem cells, the term is also used to describe therapies that use progenitor cells, used for many decades in the form of bone marrow transplants, as well as other cellular products such as platelet-rich plasma (PRP).
While both PRP and progenitor cells are widely used in clinical settings, stem cell therapies are still playing catch-up. PRP is used to treat orthopedic injuries and degenerative joint disease.
However, stem cells are in high demand worldwide. The burgeoning field of stem cell medicine is widely understood in a vague sort of way, but few people are aware that there are different kinds of stem cells. They can be derived from different tissue sources, harvested from the patient’s own body or donated. To help establish a better understanding of the stem cell landscape, we’ll start with some basic concepts.
Autologous vs. Allogenic Stem Cells
Stem cell treatments are generally divided into two classes:
- Autologous stem cells – collected from your own body, exclusively for your own use
- allogeneic stem cells, harvested from another person (donor)
Current clinical trials involving both autologous and allogeneic therapies are taking place all over the world. These trials target a wide range of diseases and conditions, from heart disease to orthopedic conditions, to wound healing.
Autologous treatments using your own stem cells can be performed in the same operative session, which eliminates concerns over your body rejecting donor cells. Your stem cells are extracted from your tissue, and reinjected back into your body targeting the area or organ that needs mending. This is a one-to-one therapy.
Allogeneic therapies use stem cells donated from another person. Before these cells can be put into a different human body than the one they came from, they must undergo extensive testing for diseases, and the cells are usually culture expanded in laboratories to achieve higher cell counts. Allogeneic therapies are performed under strict FDA guidelines, as these stem cells can eventually scale up in mass production, be stored and potentially distributed to millions of patients.
Stem Cell Types
Adult stem cells (non-embryonic) are undifferentiated cells found throughout the body that multiply by cell division to replenish dying cells and regenerate damaged tissues.
Stem cells are acquired from various tissue sources, and each tissue source has different potentials for the cells to differentiate. The following information explains these tissue sources and corresponding type of stem cells:
Adult Stem Cells (ASC’s)
In recent decades researchers discovered that stem cells can be found in all adult tissues. These are called adult stem cells, and although they cannot differentiate into every type of cell like embryonic stem cells, they can differentiate into bone, cartilage and adipose (fat) tissue readily. The two most familiar sources of adult stem cells are bone marrow and adipose tissue. More than 2,000 clinical trials have been conducted worldwide using the various tissue sources of adult stem cells.
IPS Cells (induced pluripotent cells)
IPS cells come from adult cells. Their genetic code is biologically manipulated to become pluripotent, which means they can differentiate, or become any other type of cell. Because the genetic code of IPS cells has been altered, they carry a higher risk profile than both adult stem cells and embryonic stem cells.
Embryonic Stem Cells (ES)
Embryonic stem cells, first isolated in mouse embryos in 1981, are derived from the embryo of a human fetus. Controversy has pursued embryonic stem cell research since its inception, over of ethical and religious perceptions. Embryonic stem cells are currently used mainly for research and understanding how regenerative cells work.
Types of Adult Stem Cells
Adult stem cells can be isolated from bone marrow, adipose tissue, umbilical cord blood, peripheral blood, dental pump, and other sources. Most recently, a large number of clinical trials are focusing on stem cells derived from bone marrow and adipose tissue.
Bone Marrow Stem Cells
Bone marrow stem cells were the first recognized form of adult stem cells in the body. Researchers found they could be used to help heal bone and to replace different cell types in the blood. They could also be used in cancer patients whose bone marrow was destroyed by radiation therapy or chemotherapy. Use of bone marrow stem cells is FDA approved under certain conditions.
The drawback with bone marrow stem cells is that they are difficult to extract and not abundant. In order to be used as a treatment, bone marrow stem cells must be expanded in culture in a lab. The FDA places this therapy in the category of a drug, and requires rigorous oversight and testing.
Adipose Derived Stem Cells
In 2001, researchers and plastic surgeons from the University of Pittsburgh discovered that human fat tissue is a very rich source of mesenchymal stem cells (MSCs), multipotent stromal cells that can differentiate into a variety of cell types, and the findings were published in Tissue Engineering Journal. Upon publication, this discovery stirred quite an epiphany in the medical and scientific community—until then, adult MSCs were predominantly believed to be strictly a bone marrow product.
###
- Published in Corporate News / Blog
Global Stem Cells Group and N-Biotek Collaborate to Offer Turnkey Solutions for Highly Manipulated Stem Cell Culture Expansion Labs
MIAMI, Aug. 23, 2016 – Global Stem Cells Group and its subsidiary Adimarket announce a collaborative agreement with South Korean biomedical and lab equipment manufacturer N-Biotek to offer the Total Solution highly manipulated stem cell culture expansion lab, complete with equipment, training, facilities, stem cell processing center, clean rooms, project plan and more- a total turnkey lab solution for emerging stem cell businesses and industry professionals.
The announcement marks a new chapter in GSCG’s ongoing expansion, and commitment to bring stem cell therapies to
Until now, Admarket has been GSCG’s online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals, offering basic tools and products to facilitate in-office stem cell procedures. However, through N-Biotek, Adimarket now offers the Total Solution labs and all the accoutrements. From planning to building the facility, to training and consultation, Total Solution users are equipped in every way possible to walk in and begin using their fully-equipped biotechnology lab in short order.
The collaboration with N-Biotek means GSCG and Adimarket can create a stem cell processing center for researchers who require more advanced lab environments to conduct complex research and develop processes and procedures for the fast-growing stem cell market.
The Stem Cell Total Solution is a comprehensive business solution that provides the entire stem cell processing system-from business planning to business procedures, a state-of-the-art cellular processing facility with bio safety clean rooms for stem cell processing, quality control rooms, core technology, cutting-edge equipment, installation, training-everything needed to launch a stem cell business or a enhance a medical research practice in a short period of time.
N-Biotek has been providing its Stem Cell Total Solution labs and consulting services, as well as stem cell processing technology management services, to universities, research centers, physicians and biotechnology enterprises in South Korea, China, Japan and Vietnam for years.
Highly manipulated stem cells are critical to biotechnology researchers in order to advance both fundamental knowledge of the undifferentiated cells that have the remarkable potential to develop into many different cell types in the body during early life and growth, and to find ways to use them to treat medical and cosmetic conditions non-invasively. Additionally, in many tissues, stem cells serve as a sort of internal repair system, dividing essentially without limit to replenish damaged and dead cells for as long as the person or animal they inhabit is alive.
When a stem cell divides, each new cell has the potential to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell, and this allows researchers to manipulate these extraordinary reconstructionist micro-organisms to differentiate into other cell types that can be used to treat disease and injuries affecting parts of the body from which they did not originate. For instance, a stem cell harvested from body fat can be manipulated to take on the functions of a pancreatic cell, a heart cell or a retina cell. Researchers see unlimited potential in their ability to heal wounds, cure diseases, and even prevent birth defects.
“Non-destructive manipulation of stem cells in a precise environment is key to facilitating discoveries within the biology and medical research communities,” says Benito Novas, CEO of Global Stem Cells Group. “Our collaboration with N-Biotek to deliver the Total Solution for highly manipulated stem cell culture expansion labs to emerging stem cell scientists is the next phase in GSCG’s mission to fulfill our promise of making stem cell-based therapies available to patients everywhere.
“Stem cell manipulation resulting in cells that possess the characteristics necessary for successful differentiation, transplantation, and engraftment is critical to discovering new methods for treating illness and impairments,” Novas says.
Global Stem Cells Group and N-Biotek provide Total Solution users with everything they need to culture, expand and cryopreserve stem cells right away. Each system comes with manufacture patents and full certification. All products and equipment is made to comply with, or exceed standards required for CE Certification.
N-Biotek is the only company that builds the entire stem cell processing system for clients ready to begin a stem cell business, or establish a lab facility to enhance their medical or research practice.
To learn more about the N-Biotek Stem Cell Total Solution, visit the Global Stem Cells Group website at or the AdiMarket website, email bnovas@stemcellsgroup.com, or call 305-560-5337.
About Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
About Adimarket:
Adimarket, Inc., a subsidiary of Global Stem Cells Group, is a cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals. Adimarket was founded to provide physicians and other health care professionals the tools they need to practice regenerative medicine in a medical office setting.
Motivated by a firm belief in the positive impact the practice of stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting edge treatments. Adimarket’s experienced customer service representatives provide valuable guidance and advice regarding products relevant to individual practices.
About N-Biotek:
Since 1982, N-Biotek has been the leading manufacturer of biomedical and lab equipment worldwide. The Stem Cell Total Solution lab is a culmination of years of dedication to establish compact and customized products in developing the Handy Lab-a personal lab for medical, scientific and university professionals. N-Biotek is known for its high quality, uniquely designed biomedical products and equipment and competitive pricing. Over the years, the company’s products have earned an array of patents, and all meet international standards including CE, ETL, ISO and GMP. N-Biotek also offers real-time monitoring through IT technology.
Since 2010, N-Biotek has expanded significantly, starting new businesses including a stem cell processing system and biological clean room, GMP consulting, validation services and health care services for foreign consumers in order to maintain its lead in the life science field.
To view this press release live online, please click here
###
- Published in Press Releases